Drug Development Pipeline
This program is working to advance a gene delivery vehicle that targets cells in the lung. 4D-710 is a customized adeno-associated virus (AAV) vector designed to deliver a healthy CFTR gene specifically to cells in the lungs of people with CF. This would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation.
A Phase 1 study to test the safety of 4D-710 in adults with CF is underway.
This program is sponsored by 4D Molecular Therapeutics and partially funded by the Cystic Fibrosis Foundation. It is being conducted through the Therapeutics Development Network.
Recent 4D-710 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More